Hemoglobinopathies Market Size And Forecast
Hemoglobinopathies Market was valued at USD 6.75 Billion in 2020 and is projected to reach USD 14.86 Billion by 2028, growing at a CAGR of 10.37 % from 2021 to 2028.

Growth of the global hemoglobinopathy market is mainly driven by a growing prevalence of hemoglobinopathies in developed nations, high disease occurrence in underdeveloped nations, various supportive government initiatives, and non-government organizational funding. The Global Hemoglobinopathies Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Hemoglobinopathies Market Definition
Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are inherited single-gene disorders of which sickle cell disease is the most common kind. There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathies. The disease does not have a permanent cure; this has resulted in a growing demand for new product innovations in the pharmaceutical sector.

Get | Download Sample Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=11504&utm_source=Free&utm_medium=004

Additionally, the high prevalence of the disease and the national control program are driving the need for drug therapy in developing economies. Alnylam Pharmaceuticals, Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen Idec are some of the key players in this market. These companies have invested huge sums of money in research and development of hemoglobinopathies to develop a permanent cure for this disease. NiCord, ZFP and ALN-TMP are some of the current products available in the market. Companies have adopted the strategy of collaboration and licensing to supplement their research activities.

Global Hemoglobinopathies Market Overview
The rising prevalence of conditions such as sickle cell disease (SCD) and thalassemia, coupled with the presence of a strong product pipeline for the treatment of hemoglobinopathies, is expected to fuel the market growth. It is estimated that thalassemia affects around 4.4 per 10,000 live births globally. Moreover, around 40 million thalassemia carriers are present in India. Furthermore, according to the WHO, over 330,000 babies are born with hemoglobin disorders each year. Major factors leading to the high prevalence of hemoglobinopathies include lack of awareness, unmet needs related to the treatment of sickle cell disease and thalassemia, and lack of a permanent cure.
In addition, increasing prevalence of hemoglobinopathies in developing and low-income countries is anticipated to boost the market growth over the forecast period. According to a report published by the American Society of Hematology, more than 95% of children born with thalassemia in the world are from low- and middle-income countries, and less than 5% of children born with thalassemia live in North America and the European region. Lack of awareness and high unmet needs related to the diagnosis and treatment are some of the major factors increasing the prevalence in low-income countries.

According to the CDC, the incidence of sickle cell disease trait in the U.S. was found to be 15.5 cases per 1,000 births. In addition, 1.5% of babies born in the U.S. have sickle cell trait.
Furthermore, Rising investment in the development of novel therapies is expected to provide impetus to market growth in the coming years. Major biopharmaceutical players are collaborating to develop novel therapeutics for hemoglobinopathies using the latest technology platforms. For instance, Sangamo Therapeutics, Inc. and Bioverativ have collaborated to develop therapeutics for hemoglobinopathies. Moreover, increasing approvals from the regulatory bodies for novel therapies are expected to boost the market growth. For instance, in 2019, the FDA approved Reblozyl, Adakveo, Zynteglo, and Oxbryta for the treatment of hemoglobin disorders.

However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Moreover, lack of a permanent cure for hemoglobinopathy disorders is also expected to limit the market growth. Most treatment options available focus on reducing symptoms of the disorders and the only reliable treatment available is bone marrow transplant, which is a very complex and expensive procedure and is also associated with some side effects.

Global Hemoglobinopathies Market Segmentation Analysis
The Global Hemoglobinopathies Market is segmented based on Indication Type, End-Users, Test Type and Geography.

Ask For Report Details @ https://www.verifiedmarketresearch.com/product/hemoglobinopathies-market/?utm_source=Free&utm_medium=004  

Hemoglobinopathies Market by Indication Type
• Sickle Cell Disease
• Alpha Thalassemia
• Beta Thalassemia

Based on indication type, the market has been segmented into sickle cell disease, alpha thalassemia, and beta thalassemia. Sickle cell disease segment is expected to be the most lucrative segment in the global hemoglobinopathy market owing to increasing incidences of sickle cell disease. In terms of value, sickle cell disease segment is estimated to account for 52.4% share of the global hemoglobinopathy market by 2016 end.

Hemoglobinopathies Market by End User
• Hospitals
• Diagnostic Laboratories
• Clinics

Based on major end users, the global hemoglobinopathy market is segmented into hospitals, diagnostic laboratories, and clinics. Diagnostic laboratories followed by hospitals are expected to account for the highest share of the global hemoglobinopathy market over the forecast period. In terms of value, diagnostic laboratories segment is estimated to account for the highest market share of 49.4% of the global hemoglobinopathy market by 2016 end.

Hemoglobinopathies Market by Test Type
• Red blood cell (RBC) count test
• Genetic testing, hemoglobin by high performance liquid chromatography (HPLC) test
• Hemoglobin isoelectric (Hb IEF) focusing
• Hemoglobin electrophoresis (Hb ELP) test
• Hemoglobin solubility test.

Based on the test types, the market has been segmented into red blood cell (RBC) count test, genetic testing, hemoglobin by high performance liquid chromatography (HPLC) test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin electrophoresis (Hb ELP) test, and hemoglobin solubility test. Red blood cells (RBC) count test segment currently accounts for the highest revenue of the global hemoglobinopathy market owing to the fact that it is a basic test performed prior to most hemoglobinopathy diagnosis tests. In terms of value, routine red blood cell (RBC) count segment is estimated to account for the highest market share of 30.4% by 2016 end.

Hemoglobinopathies Market by Geography
• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of regional analysis, the Global Hemoglobinopathies Market is classified into North America, Europe, Asia Pacific, and Rest of the world. Europe is estimated to be the dominant regional market in the global hemoglobinopathy market in 2016 owing to a robust healthcare infrastructure and high prevalence of thalassemia in Mediterranean countries like Cyprus and Greece. The Europe hemoglobinopathy market is expected to register a CAGR of 7.9% over the forecast period. Asia Pacific and Middle East & Africa are estimated to be the fastest growing markets in terms of CAGR. The North America hemoglobinopathy market is expected to register a CAGR of 7.6% over the forecast period.

Key Players in Hemoglobinopathies Market
The “Global Hemoglobinopathies Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Abbott Diagnostics, Bio-Rad Laboratories Inc., Danaher Corporation, Mindray Medical International Ltd., Nexcelom Bioscience LLC., Nihon Kohden Corporation, PerkinElmer Inc., Siemens Healthineers, Pfizer, Inc. and Sysmex Corporation.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

For More Information @ https://www.verifiedmarketresearch.com/download-sample/?rid=11504&utm_source=Free&utm_medium=004

 

About us –

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. VMR offers insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080

UK: +44 (753)-715-0008

APAC: +61 (488)-85-9400

US Toll-Free: +1 (800)-782-1768

Website:- https://www.verifiedmarketresearch.com/

Email: [email protected]



Try Our New Dashboard  :- https://www.verifiedmarketresearch.com/dashboard/?utm_source=Free&utm_medium=004